0RAD
vs
D
DAX Index
0RAD
Over the past 12 months, 0RAD has underperformed DAX Index, delivering a return of -39% compared to the DAX Index's +17% growth.
Stocks Performance
0RAD vs DAX Index
Performance Gap
0RAD vs DAX Index
Performance By Year
0RAD vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
